Immunome, Inc.IMNMNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank41
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Percentile
P41
Within normal range
vs 3Y Ago
-1.6x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
PeriodValue
Q4 2025-18.37%
Q3 202518.00%
Q2 20256.89%
Q1 2025-26.14%
Q4 2024-23.10%
Q3 2024-46.03%
Q2 2024-109.46%
Q1 202436.02%
Q4 2023-102.68%
Q3 2023-51.98%
Q2 2023-123.45%
Q1 2023461.71%
Q4 202211.73%
Q3 20226.07%
Q2 2022-26.41%
Q1 20226.30%
Q4 2021-64.17%
Q3 2021-10.80%
Q2 2021-5.83%
Q1 202141.69%
Q4 2020-139.79%
Q3 2020-70.81%
Q2 202028.29%
Q1 202019.97%
Q4 2019-9.33%
Q3 2019-1.20%
Q2 20190.00%
Q1 20190.00%